EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

2‐Phenylquinolines Exhibit Anti‐Severe Acute Respiratory Syndrome Coronavirus‐2 Activity Through the Nonstructural Protein 13 Helicase Inhibition

Giada Cernicchi, Maria Giulia Nizi, Roberta Emmolo, Leentje Persoons, Manon Laporte, Dirk Jochmans, Isabella Romeo, Giacomo Pepe, Ciro Milite, Pietro Campiglia, Jacopo Spezzini, Alma Martelli und 13 weitere

ChemMedChem · 2026

DOI: 10.1002/cmdc.202501063 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemMedChem, 2026. Verfasst von Giada Cernicchi und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, University of Perugia, Perugia, Italy. Hauptthemen laut MEDLINE: Antiviral Agents, SARS-CoV-2, Quinolines, Viral Nonstructural Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NextGenerationEU-MUR PNRR, PRIN 2022, Hercules Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Severe Acute Respiratory Syndrome Coronavirus‐2 (SARS‐CoV‐2) pandemic has highlighted the fragility of our therapeutic arsenal against human coronaviruses and the urgent need to develop new antivirals. They should exhibit broad‐spectrum activity to address future pandemics and target alternative viral proteins to mitigate resistance. We have previously identified a hit compound based on a 2‐phenylquinoline scaffold that is able to hinder SARS‐CoV‐2 replication through nonstructural protein 13 (nsp13) helicase inhibition. Here we reported a SAR study that led to identify new analogs such as 2‐(4‐butoxyphenyl)‐4‐[2‐(6,7‐dimethoxy‐3,4‐dihydroisoquinolin‐2(1H)‐yl)ethoxy]−5,7‐dimethoxyquinoline ( 14 ) and 4‐[2‐(6,7‐dimethoxy‐3,4‐dihydroisoquinolin‐2(1H)‐yl)ethoxy]‐2‐(4‐isopropoxyphenyl)−5,7‐dimethoxyquinoline ( 15 ), which exhibited a good antiviral profile (EC 50 = 8.06 and 9.11 µM) coupled with a low micromolar inhibition of nsp13 helicase. Time‐of‐addition assays and binding analyses confirmed helicase as their primary target, while kinetic studies revealed ATP‐competitive inhibition. The butoxy derivative 14 also inhibited HCoV‐229E and HCoV‐OC43 replication, indicating broad‐spectrum potential. The safety of the compounds was validated in bronchial epithelium cells BEAS‐2B cells and H9c2 cardiac cells, where they did not affect cell viability or reactive oxygen species (ROS) production. Finally, preliminary ADME studies on 15 showed a positive profile in terms of membrane permeability and metabolic stability in plasma and human liver microsomes. This SAR study, along with mechanistic exploration, paves the way for further optimization of 2‐phenylquinoline‐based compounds.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsSARS-CoV-2QuinolinesViral Nonstructural ProteinsRNA HelicasesHumansStructure-Activity RelationshipAnimalsVirus ReplicationCOVID-19 Drug TreatmentMethyltransferases

Stichwörter der Autor:innen

2‐phenylquinolinesantiviralshuman coronaviruses (HCoVs)nonstructural protein 13 (nsp13) helicasesevere acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2)

Substanzen

Antiviral AgentsQuinolinesViral Nonstructural ProteinsRNA HelicasesNsp13 protein, SARS-CoVMethyltransferases

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, University of Perugia, Perugia, Italy.
  • Department of Life and Environmental Sciences, University of Cagliari, Cittadella Universitaria di Monserrato, Cagliari, Italy.
  • KU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Molecular Genetics and Therapeutics in Virology and Oncology Research Group, Leuven, Belgium.
  • KU Leuven, Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Virology, Antiviral Drug & Vaccine Research Group, Leuven, Belgium.
  • Department of Health Sciences, University of "Magna Græcia" of Catanzaro, Catanzaro, Italy.
  • Department of Pharmacy, University of Salerno, Fisciano, Italy.

ORCID-Profile: Steven De Jonghe, Oriana Tabarrini

Förderung

  • NextGenerationEU-MUR PNRR
  • PRIN 2022
  • Hercules Foundation

Zitieren

APA

Cernicchi, G., Nizi, M. G., Emmolo, R., Persoons, L., Laporte, M., Jochmans, D., Romeo, I., Pepe, G., Milite, C., Campiglia, P., Spezzini, J., Martelli, A., Brogi, S., Esposito, F., Felicetti, T., Massari, S., Manfroni, G., Sabatini, S., Sbardella, G., …, & Tabarrini, O. (2026). 2‐Phenylquinolines Exhibit Anti‐Severe Acute Respiratory Syndrome Coronavirus‐2 Activity Through the Nonstructural Protein 13 Helicase Inhibition. ChemMedChem. https://doi.org/10.1002/cmdc.202501063

Vancouver

Cernicchi G, Nizi MG, Emmolo R, Persoons L, Laporte M, Jochmans D, et al. 2‐Phenylquinolines Exhibit Anti‐Severe Acute Respiratory Syndrome Coronavirus‐2 Activity Through the Nonstructural Protein 13 Helicase Inhibition. ChemMedChem. 2026. doi:10.1002/cmdc.202501063

BibTeX
@article{Cernicchi2026,
  author = {Cernicchi, Giada and Nizi, Maria Giulia and Emmolo, Roberta and Persoons, Leentje and Laporte, Manon and Jochmans, Dirk and Romeo, Isabella and Pepe, Giacomo and Milite, Ciro and Campiglia, Pietro and Spezzini, Jacopo and Martelli, Alma and Brogi, Simone and Esposito, Francesca and Felicetti, Tommaso and Massari, Serena and Manfroni, Giuseppe and Sabatini, Stefano and Sbardella, Gianluca and Alcaro, Stefano and Neyts, Johan and Corona, Angela and Tramontano, Enzo and De Jonghe, Steven and Tabarrini, Oriana},
  title = {2‐Phenylquinolines Exhibit Anti‐Severe Acute Respiratory Syndrome Coronavirus‐2 Activity Through the Nonstructural Protein 13 Helicase Inhibition},
  journal = {ChemMedChem},
  year = {2026},
  doi = {10.1002/cmdc.202501063}
}
Kostenlos starten →